trial

Artemisinin to Reduce The Symptoms of Schizophrenia

NCTId NCT00753506
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 66 (actual)
Sponsored by Sheppard Pratt Health System
Primary completion 2010-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
66 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-08
Primary completion
2010-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Artemisinin

Sponsors

Sheppard Pratt Health SystemLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Faith B Dickerson, PhD, MPHPrincipal Investigator

Sites

1 total
Towson, United States

Facts & assertions

4 sourced
Enrollment
66
Phase
NA
Primary Completion Date
2010-05
Status
COMPLETED
relationships
The graph out of here
drug
Artemisinin
drug
lead_sponsor
Sheppard Pratt Health System
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Faith B Dickerson, PhD, MPH
person